The global dystonia drugs market was valued at $806.67 million in 2021, and is projected to reach $1,378.67 million by 2031, registering a CAGR of 5.5% from 2022 to 2031. Dystonia may be defined as a movement disorder which is characterized by involuntary contraction of the muscles which causes repetitive or twisting movements. This condition may affect a single (focal dystonia) or two parts (segmental dystonia) of the body or can affect the whole body of the patient which is termed as (general dystonia). These muscle contractions can be mild or severe in nature and can affect the movement of the person due to abnormal posture. Moreover, women are more prone to the condition than the men. Symptoms of dystonia include the cramping of the foot, involuntary pulling of the neck, uncontrollable blinking, speech difficulties and others. People also suffer from pain and discomfort as a result of constant muscle contractions. However, dystonia does not have a specific cause but is known to occur as a result of problems related to basal ganglia which leads to muscle contractions in the person.
Major approaches for treating dystonia include botulinum toxin (botox) injections, several drug types of medication and surgery. These approaches can be used individually or in combination for treating dystonia. In addition, the drugs used for the treatment of dystonia includes muscle relaxants, anticholinergic drugs, anticonvulsants, dopaminergic agents and others. The response to these medications depends on different individuals and may also differ according to the severity of the condition.
The major factor driving the growth of dystonia drugs market includes the increase in incidences of dystonia in developed and developing regions, along with increase in prevalence of conditions such as Parkinson's disease, Huntington's disease and others. For instance, according to The Parkinson's Foundation, nearly 90,000 people in the U.S. are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease. As Parkison's disease and dystonia are closely related to each other, increase in prevalence of Parkinsons diseases increases the incidence of dystonia. This further increases the demand for dystonia treatment drugs and thus, propels the growth of dystonia drugs market.
In addition, major key players are offering a wide range of dystonia drug products with significant product differentiation. Manufacturers are focusing on developing novel formulations which are highly potent and effective and are easily accessible to the patients. Thus, increase in such product offering by the key market players is anticipated to increase the prescription of various dystonia medications by healthcare providers and patients and thereby augment the growth of the market.
Furthermore, the increase in funding and investment by the key market players in the developing regions is boosting the market growth. Regions such as Asia-Pacific have been the point of attraction for the investors owing to the presence of essential resources in this region. Moreover, Asia-Pacific is emerging as a pharmaceutical hub for supply of medications and devices around the globe. This also propels the growth dystonia drugs market.
Although various key factors are driving the growth of the market, there are few factors such as lack of awareness about the condition and its treatment options in underdeveloped countries is providing hindrance to the growth of the market. Dystonia is often left undiagnosed as people have less knowledge regarding the condition. Also, people in developing countries are unaware about the advanced treatment options available for dystonia. Also, availability of new alternate treatment options such as surgeries and other physical therapies, further acts as a restraint to the growth of the market.
The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants, and others. On the basis of route of administration, the market is segmented into oral and injection. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global Dystonia Drugs Market are AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma.
Major approaches for treating dystonia include botulinum toxin (botox) injections, several drug types of medication and surgery. These approaches can be used individually or in combination for treating dystonia. In addition, the drugs used for the treatment of dystonia includes muscle relaxants, anticholinergic drugs, anticonvulsants, dopaminergic agents and others. The response to these medications depends on different individuals and may also differ according to the severity of the condition.
The major factor driving the growth of dystonia drugs market includes the increase in incidences of dystonia in developed and developing regions, along with increase in prevalence of conditions such as Parkinson's disease, Huntington's disease and others. For instance, according to The Parkinson's Foundation, nearly 90,000 people in the U.S. are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease. As Parkison's disease and dystonia are closely related to each other, increase in prevalence of Parkinsons diseases increases the incidence of dystonia. This further increases the demand for dystonia treatment drugs and thus, propels the growth of dystonia drugs market.
In addition, major key players are offering a wide range of dystonia drug products with significant product differentiation. Manufacturers are focusing on developing novel formulations which are highly potent and effective and are easily accessible to the patients. Thus, increase in such product offering by the key market players is anticipated to increase the prescription of various dystonia medications by healthcare providers and patients and thereby augment the growth of the market.
Furthermore, the increase in funding and investment by the key market players in the developing regions is boosting the market growth. Regions such as Asia-Pacific have been the point of attraction for the investors owing to the presence of essential resources in this region. Moreover, Asia-Pacific is emerging as a pharmaceutical hub for supply of medications and devices around the globe. This also propels the growth dystonia drugs market.
Although various key factors are driving the growth of the market, there are few factors such as lack of awareness about the condition and its treatment options in underdeveloped countries is providing hindrance to the growth of the market. Dystonia is often left undiagnosed as people have less knowledge regarding the condition. Also, people in developing countries are unaware about the advanced treatment options available for dystonia. Also, availability of new alternate treatment options such as surgeries and other physical therapies, further acts as a restraint to the growth of the market.
The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants, and others. On the basis of route of administration, the market is segmented into oral and injection. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global Dystonia Drugs Market are AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dystonia drugs market analysis from 2021 to 2031 to identify the prevailing dystonia drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the dystonia drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global dystonia drugs market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Drug Type
- Anticonvulsants drugs
- Dopaminergic agents
- GABAergic agents
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Online Providers
- Drug Stores and Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Hameln Pharma Gmbh
- Ipsen Pharma
- Novartis AG
- Pfizer Inc.
- Wellona Pharma
- Teva Pharmaceutical Industries Limited
- Amneal Pharmaceuticals LLC
- F. Hoffmann-La Roche Ltd.
- Merz Pharmaceuticals, LLC
- Abbvie Inc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in R&D activities in pharmaceutical field
3.4.1.2. Increase in incidences of dystonia
3.4.1.3. Increase in prevalence of neurological disorders
3.4.2. Restraints
3.4.2.1. Lack of awareness about dystonia in underdeveloped nations
3.4.3. Opportunities
3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: DYSTONIA DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Dopaminergic agents
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. GABAergic agents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Anticonvulsants drugs
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: DYSTONIA DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbvie Inc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. F. Hoffmann-La Roche Ltd.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Hameln Pharma Gmbh
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Ipsen Pharma
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Merz Pharmaceuticals, LLC
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Key strategic moves and developments
9.6. Novartis AG
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Pfizer Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Wellona Pharma
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Teva Pharmaceutical Industries Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Amneal Pharmaceuticals LLC
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
List of Tables
Table 01. Global Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 02. Dystonia Drugs Market for Dopaminergic Agents, by Region, 2021-2031 (Revenue, $Million)
Table 03. Dystonia Drugs Market for Gabaergic Agents, by Region, 2021-2031 (Revenue, $Million)
Table 04. Dystonia Drugs Market for Anticonvulsants Drugs, by Region, 2021-2031 (Revenue, $Million)
Table 05. Dystonia Drugs Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 06. Global Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 07. Dystonia Drugs Market for Oral, by Region, 2021-2031 (Revenue, $Million)
Table 08. Dystonia Drugs Market for Injectable, by Region, 2021-2031 (Revenue, $Million)
Table 09. Global Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 10. Dystonia Drugs Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 11. Dystonia Drugs Market for Online Providers, by Region, 2021-2031 (Revenue, $Million)
Table 12. Dystonia Drugs Market for Drug Stores and Retail Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 13. Dystonia Drugs Market, by Region, 2021-2031 (Revenue, $Million)
Table 14. North America Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 15. North America Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 16. North America Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 17. North America Dystonia Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 18. U.S. Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 19. U.S. Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 20. U.S. Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 21. Canada Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 22. Canada Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 23. Canada Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 24. Mexico Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 25. Mexico Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 26. Mexico Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 27. Europe Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 28. Europe Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 29. Europe Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 30. Europe Dystonia Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 31. Germany Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 32. Germany Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 33. Germany Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 34. France Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 35. France Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 36. France Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 37. UK Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 38. UK Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 39. UK Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 40. Italy Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 41. Italy Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 42. Italy Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 43. Spain Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 44. Spain Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 45. Spain Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 46. Rest of Europe Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 49. Asia-Pacific Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Dystonia Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 53. Japan Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 54. Japan Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 55. Japan Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. China Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 57. China Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 58. China Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 59. Australia Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 60. Australia Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 61. Australia Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 62. India Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 63. India Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 64. India Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 65. South Korea Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 66. South Korea Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 67. South Korea Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 68. Rest of Asia-Pacific Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 70. Rest of Asia-Pacific Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 71. LAMEA Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 74. LAMEA Dystonia Drugs Market, by Country, 2021-2031 (Revenue, $Million)
Table 75. Brazil Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 76. Brazil Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 77. Brazil Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 78. Saudi Arabia Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 80. Saudi Arabia Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 81. South Africa Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 82. South Africa Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 83. South Africa Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 84. Rest of LAMEA Dystonia Drugs Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Dystonia Drugs Market, by Route of Administration, 2021-2031 (Revenue, $Million)
Table 86. Rest of LAMEA Dystonia Drugs Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 87. Abbvie Inc.: Key Executives
Table 88. Abbvie Inc.: Company Snapshot
Table 89. Abbvie Inc.: Product Segments
Table 90. Abbvie Inc.: Product Portfolio
Table 91. Abbvie Inc.: Key Strategies
Table 92. F. Hoffmann-La Roche Ltd.: Key Executives
Table 93. F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 94. F. Hoffmann-La Roche Ltd.: Product Segments
Table 95. F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 96. Hameln Pharma GmbH: Key Executives
Table 97. Hameln Pharma GmbH: Company Snapshot
Table 98. Hameln Pharma GmbH: Product Segments
Table 99. Hameln Pharma GmbH: Product Portfolio
Table 100. Ipsen Pharma: Key Executives
Table 101. Ipsen Pharma: Company Snapshot
Table 102. Ipsen Pharma: Product Segments
Table 103. Ipsen Pharma: Product Portfolio
Table 104. Merz Pharmaceuticals, LLC: Key Executives
Table 105. Merz Pharmaceuticals, LLC: Company Snapshot
Table 106. Merz Pharmaceuticals, LLC: Product Segments
Table 107. Merz Pharmaceuticals, LLC: Product Portfolio
Table 108. Merz Pharmaceuticals, LLC: Key Strategies
Table 109. Novartis AG: Key Executives
Table 110. Novartis AG: Company Snapshot
Table 111. Novartis AG: Product Segments
Table 112. Novartis AG: Product Portfolio
Table 113. Pfizer Inc.: Key Executives
Table 114. Pfizer Inc.: Company Snapshot
Table 115. Pfizer Inc.: Product Segments
Table 116. Pfizer Inc.: Product Portfolio
Table 117. Wellona Pharma: Key Executives
Table 118. Wellona Pharma: Company Snapshot
Table 119. Wellona Pharma: Product Segments
Table 120. Wellona Pharma: Product Portfolio
Table 121. Teva Pharmaceutical Industries Limited: Key Executives
Table 122. Teva Pharmaceutical Industries Limited: Company Snapshot
Table 123. Teva Pharmaceutical Industries Limited: Product Segments
Table 124. Teva Pharmaceutical Industries Limited: Product Portfolio
Table 125. Amneal Pharmaceuticals LLC: Key Executives
Table 126. Amneal Pharmaceuticals LLC: Company Snapshot
Table 127. Amneal Pharmaceuticals LLC: Product Segments
Table 128. Amneal Pharmaceuticals LLC: Product Portfolio
Table 129. Amneal Pharmaceuticals LLC: Key Strategies
List of Figures
Figure 01. Dystonia Drugs Market, 2021-2031
Figure 02. Segmentation of Dystonia Drugs Market, 2021-2031
Figure 03. Top Investment Pockets in Dystonia Drugs Market (2022-2031)
Figure 04. Moderate Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globaldystonia Drugs Market
Figure 10. Dystonia Drugs Market, by Drug Type, 2021(%)
Figure 11. Comparative Share Analysis of Dystonia Drugs Market for Dopaminergic Agents, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Dystonia Drugs Market for Gabaergic Agents, by Country 2021-2031(%)
Figure 13. Comparative Share Analysis of Dystonia Drugs Market for Anticonvulsants Drugs, by Country 2021-2031(%)
Figure 14. Comparative Share Analysis of Dystonia Drugs Market for Others, by Country 2021-2031(%)
Figure 15. Dystonia Drugs Market, by Route of Administration, 2021(%)
Figure 16. Comparative Share Analysis of Dystonia Drugs Market for Oral, by Country 2021-2031(%)
Figure 17. Comparative Share Analysis of Dystonia Drugs Market for Injectable, by Country 2021-2031(%)
Figure 18. Dystonia Drugs Market, by Distribution Channel, 2021(%)
Figure 19. Comparative Share Analysis of Dystonia Drugs Market for Hospital Pharmacies, by Country 2021-2031(%)
Figure 20. Comparative Share Analysis of Dystonia Drugs Market for Online Providers, by Country 2021-2031(%)
Figure 21. Comparative Share Analysis of Dystonia Drugs Market for Drug Stores and Retail Pharmacies, by Country 2021-2031(%)
Figure 22. Dystonia Drugs Market by Region, 2021
Figure 23. U.S. Dystonia Drugs Market, 2021-2031 ($Million)
Figure 24. Canada Dystonia Drugs Market, 2021-2031 ($Million)
Figure 25. Mexico Dystonia Drugs Market, 2021-2031 ($Million)
Figure 26. Germany Dystonia Drugs Market, 2021-2031 ($Million)
Figure 27. France Dystonia Drugs Market, 2021-2031 ($Million)
Figure 28. UK Dystonia Drugs Market, 2021-2031 ($Million)
Figure 29. Italy Dystonia Drugs Market, 2021-2031 ($Million)
Figure 30. Spain Dystonia Drugs Market, 2021-2031 ($Million)
Figure 31. Rest of Europe Dystonia Drugs Market, 2021-2031 ($Million)
Figure 32. Japan Dystonia Drugs Market, 2021-2031 ($Million)
Figure 33. China Dystonia Drugs Market, 2021-2031 ($Million)
Figure 34. Australia Dystonia Drugs Market, 2021-2031 ($Million)
Figure 35. India Dystonia Drugs Market, 2021-2031 ($Million)
Figure 36. South Korea Dystonia Drugs Market, 2021-2031 ($Million)
Figure 37. Rest of Asia-Pacific Dystonia Drugs Market, 2021-2031 ($Million)
Figure 38. Brazil Dystonia Drugs Market, 2021-2031 ($Million)
Figure 39. Saudi Arabia Dystonia Drugs Market, 2021-2031 ($Million)
Figure 40. South Africa Dystonia Drugs Market, 2021-2031 ($Million)
Figure 41. Rest of LAMEA Dystonia Drugs Market, 2021-2031 ($Million)
Figure 42. Top Winning Strategies, by Year
Figure 43. Top Winning Strategies, by Development
Figure 44. Top Winning Strategies, by Company
Figure 45. Product Mapping of Top 10 Players
Figure 46. Competitive Dashboard
Figure 47. Competitive Heatmap: Dystonia Drugs Market
Figure 48. Top Player Positioning, 2021
Figure 49. Abbvie Inc.: Net Revenue, 2019-2021 ($Million)
Figure 50. Abbvie Inc.: Revenue Share by Segment, 2021 (%)
Figure 51. Abbvie Inc.: Revenue Share by Region, 2021 (%)
Figure 52. F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 53. F. Hoffmann-La Roche Ltd.: Revenue Share by Segment, 2021 (%)
Figure 54. F. Hoffmann-La Roche Ltd.: Revenue Share by Region, 2021 (%)
Figure 55. Ipsen Pharma: Net Revenue, 2019-2021 ($Million)
Figure 56. Ipsen Pharma: Revenue Share by Segment, 2021 (%)
Figure 57. Ipsen Pharma: Revenue Share by Region, 2021 (%)
Figure 58. Novartis AG: Net Sales, 2019-2021 ($Million)
Figure 59. Novartis AG: Revenue Share by Segment, 2021 (%)
Figure 60. Novartis AG: Revenue Share by Region, 2021 (%)
Figure 61. Pfizer Inc.: Net Revenue, 2019-2021 ($Million)
Figure 62. Pfizer Inc.: Revenue Share by Segment, 2021 (%)
Figure 63. Pfizer Inc.: Revenue Share by Region, 2021 (%)
Figure 64. Teva Pharmaceutical Industries Limited: Net Revenue, 2019-2021 ($Million)
Figure 65. Teva Pharmaceutical Industries Limited: Revenue Share by Segment, 2021 (%)
Figure 66. Amneal Pharmaceuticals LLC: Net Revenue, 2019-2021 ($Million)
Figure 67. Amneal Pharmaceuticals LLC: Revenue Share by Segment, 2021 (%)
Executive Summary
According to the report titled, 'Dystonia Drugs Market' the dystonia drugs market was valued at $806.67 million in 2021, and is estimated to reach $1,378.67 million by 2031, growing at a CAGR of 5.5% from 2022 to 2031.Dystonia is referred to the condition characterized by involuntary muscle contractions which causes slow repetitive movements or abnormal postures. There are several forms of dystonia which may affect a single muscle, or a group of muscles or may affect muscles throughout the body. It causes painful movements or may lead to tremor in the patients. There is no specific treatment for dystonia but its symptoms can be relieved through used of certain medications.
Key factors driving the growth of the dystonia drugs market include increase in incidences of dystonia, increase in prevalence of neurological disorders and increase in R&D activities in pharmaceutical field. In addition, rise in demand for novel therapies is driving the growth of the market. Additionally, the increasing geriatric population, as dystonia is more common in older adults, and the growing global healthcare expenditure are also expected to drive the market.
Furthermore, the development of new and effective drugs for the treatment of dystonia is expected to drive growth in the market, as patients will have more options to choose from. The availability of a wider range of treatment options is expected to increase patient satisfaction and improve outcomes. This, in turn, is expected to drive demand for dystonia drugs and contribute to the overall growth of the market. In addition, a large number of market players are manufacturing a wide range of benzodiazepine medications that can be used in dystonia treatment regime. For instance, according to the Dystonia Network of Australia Inc., Rivotril is probably the most common type of benzodiazepine medication prescribed in Australia for dystonia treatment. Moreover, Valium (diazepam) and Ativan (lorazepam) are also commonly prescribed medications, which leads to an increase in demand for GABAergic agents' drugs for dystonia treatment. Thus, propelling the growth of the dystonia drugs market.
Increase in awareness among the people in developing regions regarding new diagnosis and treatment techniques is anticipated to drive the market in the forecast period. The government agencies are collaborating with pharmaceutical manufacturers for creating awareness among the population regarding dystonia and its treatment. This is anticipated to create awareness among the population in underdeveloped and developing countries about dystonia and is expected to boost the market growth in the near future.
In addition, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for pharmaceutical market players. An emerging economy often experiences rapid economic growth which means that the emerging economy is increasing its production of goods and services. This might result from an increased population in the country or a growth in human capital. In addition, surge in healthcare industry, industrial development, and investments from developed countries in Asia-Pacific, along with rise in awareness regarding new diagnosis and treatment approaches for various neurological conditions is anticipated to positively impact the market during the forecast period.
The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants drugs, and others. On the basis of route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and Drug Stores and Retail Pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma Gmbh, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma. The players in the market have been actively engaged in the adoption various Strategies such as acquisition, collaboration, agreement and expansion to remain competitive and gain advantage over the competitors in the market. For instance, in January 2023, Amneal Pharmaceuticals, Inc. announced a long-term license agreement with Orion Corporation to commercialize a number of Amneal's complex generic products in to market in Europe, Australia, and New Zealand.
Key Market Insights
- By drug type, the GABAergic agent's segment was highest contributor to the market in 2021 and is estimated to reach $501.28 million by 2031, with a CAGR of 6.4%.
- By route of administration, the oral segment dominated the global market. However, the injectable segment is expected to be the fastest-growing segment with a CAGR of 6.6% during the forecast period.
- Based on distribution channel, the drug stores and retail pharmacies segment was the highest revenue contributor to the market and the online providers is estimated be the fastest growing segment during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest rate during the forecast period.
Companies Mentioned
- Hameln Pharma Gmbh
- Ipsen Pharma
- Novartis AG
- Pfizer Inc.
- Wellona Pharma
- Teva Pharmaceutical Industries Limited
- Amneal Pharmaceuticals LLC
- F. Hoffmann-La Roche Ltd.
- Merz Pharmaceuticals, LLC
- Abbvie Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | January 2023 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 806.67 million |
| Forecasted Market Value ( USD | $ 1378.67 million |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
